R. Huff

发表

Physical and immunological characterization of a guanine nucleotide-binding protein purified from bovine cerebral cortex.

E. Neer, R. Huff, J. Axton, 1985, The Journal of biological chemistry.

Sumanirole, a Highly Dopamine D2-Selective Receptor Agonist: In Vitro and in Vivo Pharmacological Characterization and Efficacy in Animal Models of Parkinson's Disease

R. Mccall, P. Bédard, K. Lookingland, 2005, Journal of Pharmacology and Experimental Therapeutics.

Signaling mechanisms of D2, D3, and D4 dopamine receptors determined in transfected cell lines. Discussion

Caron, Schwartz, Van Tol, 1995 .

In vivo electrochemistry: behavior of micro electrodes in brain tissue

R. Adams, J. O. Schenk, R. Huff, 1979 .

Amphetamine dose-dependent changes of in vivo electrochemical signals in rat caudate

R. Adams, C. Rutledge, R. Huff, 1979, Brain Research.

Chapter 5. Recent Advances in Dopamine D3 and D4 Receptor Ligands and Pharmacology

R. Huff, E. TenbrinkRuth, 1994 .

Anion-exchange high-performance liquid chromatographic analysis of inositol phosphates.

W. Mathews, D. M. Guido, R. Huff, 1988, Analytical biochemistry.

Anti-Inflammatory Properties of CB 1 -Receptor Antagonist Involves (cid:1) 2 Adrenoceptors

S. Mnich, R. Hiebsch, S. Muthian, 2010 .

Piperazinyl-glutamate-pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation.

S. Rapp, M. D. Ennis, T. Girard, 2009, Bioorganic & medicinal chemistry letters.

A Comprehensive Method for the Quantitative Determination of Dopamine Receptor Subtypes a

P. Molinoff, P. Mcgonigle, R. Huff, 1984, Annals of the New York Academy of Sciences.

Piperazinyl glutamate pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation.

S. Rapp, M. D. Ennis, P. Harris, 2010, Journal of medicinal chemistry.

Part II: piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation.

S. Rapp, M. D. Ennis, P. Harris, 2010, Bioorganic & medicinal chemistry letters.

Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors.

M. E. Lajiness, F. Schneider, J. Mierau, 1995, European journal of pharmacology.

Pre- and postsynaptic dopaminergic activities of U-86170F

D. Evans, R. Lahti, R. Huff, 1991, Naunyn-Schmiedeberg's Archives of Pharmacology.

(S)-(-)-4-[4-[2-(isochroman-1-yl)ethyl]-piperazin-1-yl] benzenesulfonamide, a selective dopamine D4 antagonist.

R. Lahti, M. Smith, S A Rees, 1996, Journal of medicinal chemistry.

Pharmacological characterization of U-101387, a dopamine D4 receptor selective antagonist.

M. Piercey, R. Mccall, K. Merchant, 1996, The Journal of pharmacology and experimental therapeutics.

Dopamine D(3) receptor antagonists. 1. Synthesis and structure-activity relationships of 5,6-dimethoxy-N-alkyl- and N-alkylaryl-substituted 2-aminoindans.

A. Carlsson, N. F. Nichols, K. Svensson, 2001, Journal of medicinal chemistry.

Piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation.

S. Rapp, M. D. Ennis, T. Girard, 2009, Bioorganic & medicinal chemistry letters.

Signal transduction pathways modulated by the D2 subfamily of dopamine receptors.

R. Huff, 1996, Cellular signalling.

Signaling Pathways Modulated by Dopamine Receptors

R. Huff, 1997 .

Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors.

M. E. Lajiness, R. Huff, C. Chio, 1994, Molecular pharmacology.

Anti-Inflammatory Properties of CB1-Receptor Antagonist Involves β2 Adrenoceptors

S. Mnich, R. Hiebsch, S. Muthian, 2010, Journal of Pharmacology and Experimental Therapeutics.

Localization of dopamine D4 receptors in GABAergic neurons of the primate brain

P. Goldman-Rakic, C. Bergson, L. Mrzljak, 1996, Nature.

D4 dopamine receptor-mediated signaling events determined in transfected Chinese hamster ovary cells.

J. Slightom, R. Drong, D. Riley, 1994, The Journal of biological chemistry.

Assay of dopamine receptors with [alpha-3H]flupenthixol.

P. Molinoff, R. Huff, 1985, The Journal of pharmacology and experimental therapeutics.

Subunit interactions of native and ADP-ribosylated alpha 39 and alpha 41, two guanine nucleotide-binding proteins from bovine cerebral cortex.

E. Neer, R. Huff, 1986, The Journal of biological chemistry.

Dopamine release in N. accumbens and striatum by clozapine: Simultaneous monitoring by in vivo electrochemistry

R. Adams, R. Huff, 1980, Neuropharmacology.

Behavioral and neurochemical data suggest functional differences between dopamine D2 and D3 receptors.

A. Carlsson, K. Svensson, N. Waters, 1994, European journal of pharmacology.

Quantitative Assay of Dopamine Receptor Subtypes

P. Molinoff, R. Huff, 1984 .

Preclinical Studies Characterizing the Anti-Migraine and Cardiovascular Effects of the Selective 5-HT1D Receptor Agonist PNU-142633

M. Ennis, R. Tenbrink, R. Huff, 2002, Cephalalgia : an international journal of headache.

A second molecular form of D2 dopamine receptor in rat and bovine caudate nucleus

G. F. Hess, R. Huff, C. Chio, 1990, Nature.

Quantitative determination of dopamine receptor subtypes not linked to activation of adenylate cyclase in rat striatum.

P. Molinoff, R. Huff, 1982, Proceedings of the National Academy of Sciences of the United States of America.

Signal transduction pathways modulated by D2-like dopamine receptors.

M. E. Lajiness, L. Goodman, R. Huff, 1998, Advances in pharmacology.

Thienopyrimidine-based P2Y12 platelet aggregation inhibitors.

B. Schweitzer, M. D. Ennis, G. Yalamanchili, 2009, Bioorganic & medicinal chemistry letters.

Sumanirole, a Highly Dopamine D2-Selective Receptor Agonist: In Vitro and in Vivo Pharmacological Characterization and Efficacy in Animal Models of Parkinson's Disease

R. Mccall, P. Bédard, K. Lookingland, 2005, Journal of Pharmacology and Experimental Therapeutics.